Posted on

cbd oil for colitis

Here are the most common ways people take CBD for ulcerative colitis:

However, studies also show that the anti-inflammatory and analgesic effects of CBD are enhanced when you introduce some THC to an extract (along with other cannabinoids and terpenes). Researchers argue that even 1% of THC in a cannabis strain can significantly improve the plant’s therapeutic potential.

If you decide to try CBD for ulcerative colitis or Crohn’s disease, it’s important to choose a form that will be the most beneficial. CBD is available in oil drops, capsules, edibles, vapes, and topicals; each of these products has different bioavailability, addresses different problems, and suits different types of users.

How to Use CBD Oil for Crohn’s Disease and Ulcerative Colitis?

There are no official recommendations when it comes to dosing CBD for ulcerative colitis and other inflammatory bowel diseases. If you want to get a decent point of reference, we suggest that you review the dosage of past human clinical trials to determine the safe amount for intake.

This question is difficult to answer due to the current state of scientific knowledge on using cannabis for IBD. In other words, the majority of studies suggest that using whole-plant extracts with various ratios of CBD and THC appear to provide the best results for ulcerative colitis and Crohn’s disease. No clinical trial has yet investigated the safety and efficacy of isolated CBD and THC for IBD.

There is no clear explanation of what causes inflammatory bowel diseases, and as of right now, scientists are still trying to find a cure for them.

The patent says, “Cannabinoids have been found to have antioxidant properties… [making them] useful in the treatment of a wide variety of oxidation associated diseases, [including] inflammatory and autoimmune diseases.”

Cannabis and cannabinoids are often promoted as treatment for many illnesses and are widely used among patients with ulcerative colitis (UC). Few studies have evaluated the use of these agents in UC. Further, cannabis has potential for adverse events and the long-term consequences of cannabis and cannabinoid use in UC are unknown.

Conclusions

To assess the efficacy and safety of cannabis and cannabinoids for the treatment of patients with UC.

The effects of cannabis and cannabidiol on UC are uncertain, thus no firm conclusions regarding the efficacy and safety of cannabis or cannabidiol in adults with active UC can be drawn.There is no evidence for cannabis or cannabinoid use for maintenance of remission in UC. Further studies with a larger number of patients are required to assess the effects of cannabis in UC patients with active and quiescent disease. Different doses of cannabis and routes of administration should be investigated. Lastly, follow-up is needed to assess the long term safety outcomes of frequent cannabis use.

The study comparing cannabis oil capsules to placebo found no difference in remission rates at 10 weeks. Twenty four (7/29) percent of cannabidiol participants achieved clinical remission compared to 26% (8/31) of placebo participants. The study also showed higher self reported quality of life scores in cannabis oil participants compared to placebo participants. More side-effects were observed in the cannabis oil participants compared to the placebo participants. These side effects were considered to be mild or moderate in severity. Common reported side effects include dizziness, disturbance in attention, headache, nausea and fatigue. No patients in the cannabis oil group had any serious side effects. Ten per cent (3/31) of the placebo group had a serious side effect. Serious side effects in the placebo group included worsening ulcerative colitis and one complicated pregnancy.

Two authors independently screened search results, extracted data and assessed bias using the Cochrane risk of bias tool. The primary outcomes were clinical remission and relapse (as defined by the primary studies). Secondary outcomes included clinical response, endoscopic remission, endoscopic response, histological response, quality of life, C-reactive protein (CRP) and fecal calprotectin measurements, symptom improvement, adverse events, serious adverse events, withdrawal due to adverse events, psychotropic adverse events, and cannabis dependence and withdrawal effects. We calculated the risk ratio (RR) and corresponding 95% confidence interval for dichotomous outcomes. For continuous outcomes, we calculated the mean difference (MD) and corresponding 95% CI. Data were pooled for analysis when the interventions, patient groups and outcomes were sufficiently similar (determined by consensus). Data were analyzed on an intention-to-treat basis. GRADE was used to evaluate the overall certainty of evidence.

The researchers evaluated whether cannabis or cannabis oil (cannabidiol) was better than placebo (e.g. fake drug) for treating adults with active ulcerative colitis or ulcerative colitis that is in remission. The researchers searched the medical literature extensively up to 2 January 2018.

Jami Kinnucan, Gastroenterologist, University of Michigan.

Does either help with UC? Some researchers and doctors are exploring the possibility that cannabis in one form or another helps people with inflammatory bowel disorders including UC. Based on the evidence so far, the answer isn’t a simple yes or no.

But, Kinnucan says, this doesn’t mean using cannabis is a good way to treat UC. That’s because people with UC have inflammation in their digestive tracts. This inflammation as well as ulcers is tied to UC symptoms, including diarrhea, pain, cramping, bleeding and fatigue. A primary aim of treatment is to stop the inflammation.

Weigh the Risks

“At the end of day, if the hope is to control inflammation, there is no data to support that,” Kinnucan says.

Harvard Health: “Cannabidiol (CBD) — what we know and what we don’t.”

Mayo Clinic: “ Medical marijuana,” “Ulcerative Colitis,” “What are the benefits of CBD — and is it safe to use?”

In addition to whether it works, doctors and patients also have legal issues to consider when it comes to cannabis. CBD is federally legal as long as it contains only very low levels of THC, although the rules in particular states could change.